Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Acorus gramineus extract is a botanical extract derived from the rhizome of the *Acorus gramineus* Solander plant, commonly known as grass-leaved sweet flag. Traditionally used in Asian medicine for central nervous system (CNS) disorders, the extract is being investigated for its anti-neuroinflammatory and neuroprotective effects, particularly in the context of Parkinson's disease. Its mechanism of action involves the inhibition of pro-inflammatory mediators, including nitric oxide (NO), tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and interleukin-1 beta (IL-1beta), by modulating the NF-kappaB, MAPK, and TRIF-dependent signaling pathways in activated microglia. Preclinical studies in MPTP-induced mouse models suggest it can prevent neuronal cell death and mitigate neuroinflammation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on acorus gramineus extract.